Markets
Jeffery Simmons #98 of the Tennessee Titans and AFC participates in Tug of War during the 2025 NFL Pro Bowl Games at Camping World Stadium on February 02, 2025 in Orlando, Florida. (Photo by Perry Knotts/Getty Images)
(Perry Knotts/Getty Images)

Financial markets and the US economy are in a tug-of-war between two paradoxes

Jevons Paradox is your reigning bull case. After July payrolls underwhelmed, enter the Paradox of Thrift.

Luke Kawa

Let’s not overcomplicate matters. The strong performance of US stocks this year is really down to two things:

1) President Donald Trump didn’t completely blow up global commerce with tariffs.

2) Jevons Paradox — the idea that as technological advances make something (in this case chips!) more efficient, you’ll still end up using more rather than less — soundly trounced DeepSeek’s seeming “Moneyball” approach to AI development.

Jevons Paradox in the current setup doesn’t mean you just buy more chips. It means you buy more servers to house those chips. And you’re going to want to buy circuits and fiber-optic cables to connect everything together, not to mention cooling equipment to make sure all your high-powered tech doesn’t run too hot. And that’s all going to be put in a data center you have to build, which will need immense amounts of power to run.

All that means that there’s currently an entire trickle-down ecosystem of profits built off of US megacap tech companies’ devotion to Jevons Paradox. Tax changes have made it materially easier for companies to keep pursuing this spending binge. And the market, by and large, is rewarding it. Why should that change?

At its core, this represents the bull case for US stocks. Don’t believe me? Well, since the February 19 pre-tariff peak for the SPDR S&P 500 ETF, total returns can be completely attributed to just three stocks: Nvidia, Microsoft, and Broadcom.

The Paradox of Thrift, however, encapsulates the bear case. It’s the idea that we can’t all tighten our belts at the same time. My spending is your income; when too many people either try to spend less (or people lose their incomes because companies decide they need to spend less!), overall economic activity goes down. With US nonfarm payroll growth coming in at just 73,000 in July, below expectations for 104,000, as the unemployment rate edged higher, worries about downside risk to the labor market are likely to assume more prominence.

Just look at some of the companies doing the most spending, as well as the single largest beneficiary: Alphabet, Amazon, Meta, Microsoft, and Nvidia, a quintet Peachtree Creek Investments’ Conor Sen dubbed the “AI 5.”

Unless Nvidia boosted payrolls by 13,505 (roughly equivalent to all the jobs the chipmaker has added since early 2022), employment in this cohort will be down quarter on quarter.

Of course, in aggregate, megacap tech companies are boosting their outlays to such an extent that it far outstrips any potential reduction in labor costs. And “reduction in labor costs” is certainly not a phrase we can associate with Mark Zuckerberg these days.

Amazon CEO Andy Jassy said that “in the next few years,” he expects that applying generative AI and agents “will reduce our total corporate workforce.”

For some companies, the future is now. Crowdstrike, Duolingo, IBM, and Salesforce have either cut jobs due to AI or said they’re hiring less than they otherwise would have. And in the background, we can’t forget about the many companies that aggressively pursued cost reductions ahead of potential worst-case scenarios for tariffs (which offers higher profitability in the near term for some!), but down the road, again, I refer you to the Paradox of Thrift.

The big problem is not that AI is going to imminently take your job. It’s merely that the marginal dollar is more likely to go to these capital expenditures than spending on labor at a time when consumption — the fruits of one’s labor income — is looking shakier.

Economic shifts happen on the margins. As the AI economy runs red-hot, other key parts (notably housing) are deep in the dumps. It’s the trouble with averages: if your head and torso are in the oven while your feet are in the freezer, in aggregate, everything seems normal, even if what you’re experiencing is two different extremes. Such is the case of the US economy.

Consumers aren’t spending less, but the growth in their spending has decelerated substantially. Nominal consumption has expanded by just 1.4% year to date through June, the slowest six-month growth since August 2020.

The good news is that income growth is increasing at nearly twice that rate; the mixed news is that much of that is down to transfer payments rather than labor market strength. Further complicating attempts to untangle how the US consumer is really doing are changes to immigration policy that signal supply, not just demand, is helping explain some of the softening.

These two paradoxes — Jevons and Thrift — are diametrically opposed to one another. One involves spending a lot; one involves spending less. It’s quite rare to see signs of both coexisting at the same time.

And you barely have to squint to do so. We’re in a prolonged period of decelerating growth in consumer spending accompanied by accelerating growth in S&P 500 capex:

Capex vs consumer spending

Capital expenditures, at the S&P 500 level, are often a lagged response to dynamics that incentivize more production, which usually means accelerating consumer spending or a big spike in key commodity prices. During this boom, those factors have either not been present, or, given the low weight of energy and material companies in the benchmark US stock index, not pertinent.

In the end, all revenue generation is a function of end-user demand. We usually tend to call that end-user “the consumer.”

We’re currently running an experiment on how much business investment in what is being billed as a labor-saving (and in many cases, labor-replacing) technology can be divorced from the consumer.

It’s difficult to imagine a world where the consumer ultimately doesn’t win out. So either the net impact of all this investment — not to mention the wealth effect from stock market gains — will be to persistently boost incomes and spending, or the consumer will win by losing and dragging everything else down with them: lower spending weighing on ad revenues, tighter credit conditions crimping demand from the hyperscalers’ customers, and so on.

Or something completely novel will happen!

More Markets

See all Markets
markets

Trump administration says tariffs on Chinese semiconductor imports are coming... in 2027

After a year-long investigation into China’s tactics to bolster its domestic semiconductor industry, the US has determined that its practices are “unreasonable” and is going to do something about that in 18 months.

The Trump administration’s office of the US trade representative said today that it plans to impose tariffs on imports of Chinese semiconductors at a rate higher than 0% to be decided at least 30 days before June 23, 2027.

“China’s pursuit of its dominance goals has severely disadvantaged US companies, workers, and the U.S. economy generally through lessened competition and commercial opportunities and through the creation of economic security risks from dependencies and vulnerabilities,” per the USTR’s notice of action.

These levies, should they come to pass, would apply to silicon, diodes, transistors, and more.

US markets were completely unbothered by this revelation, likely because there is no immediate action against Chinese semi companies and therefore no disruption to business-as-usual. This represents a punting of a contentious matter, similar to how China delayed restrictions on rare earth shipments as part of a deal between Presidents Trump and Xi following their October meeting.

It’s another sign of a thaw in the US-China relations over the hot-button issue of semiconductors after President Trump gave Nvidia the go-ahead to sell its H200 chips to buyers in the world’s second-largest economy.

markets

ServiceNow strikes deal to buy cybersecurity firm Armis for $7.75 billion in cash

ServiceNow has agreed to acquire cybersecurity startup Armis for $7.75 billion in an all-cash deal, the largest purchase in the company's history.

That price tag is $750 million above what Bloomberg suggested was the top end of what Armis would cost just last week, and about $1.65 billion above what the company had been valued at in a November funding round.

Armis had been readying itself for an IPO, with many major investors looking to take a stake in the firm.

Instead, it’s now a key cog in the software platform company’s bid to lean on cybersecurity features to bolster its appeal to customers in a world in which the rise of AI adds to the potential threats of business disruptions and data breaches.

Per the press release:

As rapid AI adoption expands the attack surface for organizations, real-time visibility into vulnerabilities and actionable insights for what to fix first are critical to minimize risk and strengthen security posture. The acquisition of Armis will extend and enhance ServiceNow’s Security, Risk, and OT portfolios in critical and fast-growing areas of cybersecurity and drive increased AI adoption by strengthening trust across businesses’ connected environments.

markets

Novo Nordisk rallies after FDA weight loss pill approval

Novo Nordisk’s US-listed shares are up 7% in pre-market trading on Tuesday after the US Food and Drug Administration approved its Wegovy weight loss pill on Monday evening.

Now the first pill of its kind to receive approval from the regulator, Novo’s Wegovy pill is expected to launch in the US in early January 2026, and awaits the European Medicines Agency and other regulatory authorities’ approval after submitting for review in the second half of 2025, per the company’s press release. The 1.5 milligram starting dose of the pill will be sold at an introductory price of $149 a month.

“The pill is here. With today's approval of the Wegovy® pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy® injection,” said Mike Doustdar, president and CEO of Novo Nordisk.

The approval was based on Novo’s Oasis 4 trial, which found participants who took 25 milligram doses of Wegovy pills daily lost 16.6% of their body weight over a 64 week period.

The approval will give Novo — which lost more than 50% of its market cap this year after Eli Lilly took the crown in weekly US prescriptions for injectable weight-loss drugs with its product Zepbound — a first-mover advantage in the expanding market. Lilly, which is down some 1% in pre-market trading today, has said its own oral drug orforglipron could be approved by March 2026.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.